Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0

作者：

Craig Leonardi

Kristian Reich

Peter Foley

Hideshi Torii

Sascha Gerdes

Lyn Guenther

Melinda Gooderham

Laura K. Ferris

Christopher E. M. Griffiths

Hany ElMaraghy

Heidi Crane

Himanshu Patel

Russel Burge

Gaia Gallo

David Shrom

Ann Leung

Chen-Yen Lin

Kim Papp

机构：

[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing

[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute

[3] Skinflammation® Center,Division of Dermatology

[4] The University of Melbourne,Psoriasis

[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology

[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital

[7] Guenther Dermatology Research Centre,undefined

[8] SkiN Centre for Dermatology and Probity Medical Research,undefined

[9] University of Pittsburgh Medical Center,undefined

[10] University of Manchester,undefined

[11] Eli Lilly and Company,undefined

[12] Lilly Corporate Center,undefined

[13] Syneos Health,undefined

[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined

来源：

Dermatology and Therapy | 2020年 / 10卷

关键词：

Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：431 / 447

页数：16

共 50 条

[21] Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a Phase 3 trial
Warren, R. B.
Morita, A.
Menter, A.
Duffin, K. Callis
Langley, R.
Amato, D.
Dennehy, E. B.
Kerr, L. N.
Shrom, D.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 79
[22] Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
Warren, Richard B.
Lebwohl, Mark
Thaci, Diamant
Gooderham, Melinda
Pinter, Andreas
Paul, Carle
Gisondi, Paolo
Szilagyi, Balint
White, Katy
Deherder, Delphine
Staelens, Fabienne
Lambert, Jeremy
Strober, Bruce
BRITISH JOURNAL OF DERMATOLOGY, 2025,
[23] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
Armstrong, April W.
Lynde, Charles W.
McBride, Sandy R.
Stahle, Mona
Edson-Heredia, Emily
Zhu, Baojin
Amato, David
Nikai, Enkeleida
Yang, Fan Emily
Gordon, Kenneth B.
JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
[24] Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
Richard G. B. Langley
Kristian Reich
Vibeke Strand
Steven R. Feldman
Carle Paul
Kenneth Gordon
Richard B. Warren
Darryl Toth
Enkeleida Nikaï
Baojin Zhu
Orin Goldblum
Emily Edson-Heredia
Hilde Carlier
Russel Burge
Chen-Yen Lin
Kristin Hollister
Matthias Augustin
Quality of Life Research, 2020, 29 : 369 - 380
[25] Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
Langley, Richard G. B.
Reich, Kristian
Strand, Vibeke
Feldman, Steven R.
Paul, Carle
Gordon, Kenneth
Warren, Richard B.
Toth, Darryl
Nikai, Enkeleida
Zhu, Baojin
Goldblum, Orin
Edson-Heredia, Emily
Carlier, Hilde
Burge, Russel
Lin, Chen-Yen
Hollister, Kristin
Augustin, Matthias
QUALITY OF LIFE RESEARCH, 2020, 29 (02) : 369 - 380
[26] Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab
Gao, Xinghua
Pan, Weili
Zheng, Min
Li, Fuqiu
Dong, Xiuqin
Lv, Dong
Guo, Zaipei
Li, Jinnan
Wang, Xuan
Geng, Songmei
ADVANCES IN THERAPY, 2025, 42 (01) : 334 - 347
[27] Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
Chiricozzi, Andrea
Megna, Matteo
Giunta, Alessandro
Carrera, Carlo Giovanni
Dapavo, Paolo
Balato, Anna
Malagoli, Piergiorgio
Mazzoccoli, Stella
Parodi, Aurora
Sabatino, Silvia
Buzzoni, Carlotta
Huang, Chu-Han
Narcisi, Alessandra
JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
[28] Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: results from UNCOVER-2, a randomized Phase 3 trial
Warren, R. B.
Feldman, S. R.
Paul, C.
Strand, V.
Burge, R.
Lin, C. -Y.
Goldblum, O. M.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 71 - 71
[29] Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)
Malagoli, Piergiorgio
Dapavo, Paolo
Pavia, Giulia
Amoruso, Fabrizio
Argenziano, Giuseppe
Bardazzi, Federico
Burlando, Martina
Carrera, Carlo G.
Damiani, Giovanni
Dini, Valentina
Girolomoni, Giampiero
Guarneri, Claudio
Loconsole, Francesco
Narcisi, Alessandra
Sampogna, Francesca
Travaglini, Massimo
Costanzo, Antonio
DERMATOLOGIC THERAPY, 2022, 35 (08)
[30] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Meeuwis, K.
Sullivan, J.
Cather, J. C.
Yosipovitch, G.
Gottlieb, A. B.
Merola, J. F.
Duffin, K. Callis
Fretzin, S.
Osuntokun, O. O.
Burge, R.
Naegeli, A. N.
Yang, F. E.
Lin, C. -Y.
Todd, K.
Bleakman, A. Potts
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 844 - 852

← 1 2 3 4 5 →